Stephen Lutz

Stephen Lutz has worked in the biopharmaceutical industry for over a decade. Stephen began their career in 2009 as a Research Technician at Massachusetts General Hospital, where they worked on identifying molecular genetic features of tumors that predict responsiveness to targeted drug therapies. In 2011, they became a Research Associate at Excelimmune, Inc., a biopharmaceutical company specializing in the development of fully human recombinant polyclonal antibodies for therapeutic use. Stephen then moved to Cell Signaling Technology in 2012, where they worked as a Research Associate. In 2015, Stephen joined Bluefin BioMedicine as an Associate Scientist, and most recently, they have been a Senior Associate Scientist II at Seismic Therapeutics since 2022.

Stephen Lutz earned a Bachelor of Science degree in Biology from the University of Vermont in 2009. Stephen attended the University of Vermont from 2005 to 2009.